Intuitive Surgical
A razor-and-blades model in medical technology: sell the robot once, then earn recurring revenue on every procedure.
A razor-and-blades model in medical technology: sell the robot once, then earn recurring revenue on every procedure.
Generate a structured, educational breakdown of ISRG, business model, moat, risks, bull/bear case.
Overview
Intuitive Surgical makes the da Vinci robotic surgery system. Hospitals buy or lease the robot, then buy instruments and service for every operation. It shows how an installed base can turn one-off sales into recurring revenue.
What the company does
Intuitive designs, makes and services robotic systems for minimally invasive surgery, along with the single-use or limited-use instruments they require and surgeon training.
How it makes money
System sales and leases, then recurring revenue from instruments and accessories used in each procedure and yearly service contracts. Recurring revenue makes up the large majority of sales.
Moat / competitive advantage
A very large installed base, thousands of surgeons trained on its systems, long clinical data records and regulatory approvals that take competitors years to match.
Business model breakdown
- •Systems: the robot itself, sold or leased to hospitals.
- •Instruments and accessories: used and replaced with each procedure.
- •Services: maintenance contracts on installed robots.
- •Training and ecosystem that keep surgeons loyal to the platform.
Key financial concepts to understand
- Procedure growth
- How fast the number of surgeries on its systems grows, the main driver of recurring revenue.
- Recurring revenue
- Income that repeats each year, such as instruments and service, rather than one-off system sales.
- Gross margin
- What is kept from sales after production costs, high for instruments and software-like services.
Bull case
- •Every new robot adds years of recurring revenue
- •Surgeon training creates high switching costs
- •Room to expand into more procedure types and countries
Bear case
- •Competition may push down prices
- •Procedure growth could slow as main markets mature
- •Valuation leaves little room for disappointment
Main risks
- •New robotic competitors from large medical device companies
- •Hospital budget pressure delaying system purchases
- •Regulatory or safety issues
- •A high valuation that assumes years of strong growth
Valuation questions to ask
- •How fast are procedures growing, and is it slowing?
- •What share of revenue is recurring?
- •What growth rate does the current price assume?
What could break the thesis
- •Procedure growth slowing sharply for several quarters.
- •A competitor winning significant hospital share.
- •A safety issue damaging trust in robotic surgery.
What beginners should learn
How the razor-and-blades model works: the first sale matters less than the recurring purchases that follow.
Key terms beginners should know
- Razor-and-blades
- Selling a base product, then earning ongoing revenue from consumables.
- Installed base
- The number of systems already in use by customers.
- Switching costs
- The time, money or effort needed to change to a competitor.
Questions to research next
- •How many systems are installed and how fast is that growing?
- •What is revenue per procedure trending toward?
- •Which competitors have received regulatory approval?
Educational disclaimer
This is an educational case study, not a buy or sell recommendation. The goal is to help you understand how to analyze a real business. Its model, its risks, and the questions a serious investor asks before committing capital. Always do your own research and consult a qualified financial professional before investing.
Run ISRG through the Analyzer to see a structured, AI-assisted educational report.